Skip to main content
Prostate CancerDiagnostics and screeningProstate healthCancerMen's healthDrugPhase 3

What this study is

The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.

What's being tested

  • 64Cu-SAR-bisPSMA

    Intervention · DRUG

    All Patients will receive a single administration, a bolus injection of 200MBq 64Cu-SAR-bisPSMA.

Study details

Official title
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy: A Prospective, Single-arm, Multi-center, Blinded-review, Phase 3 Diagnostic Performance Study
Sponsor
Clarity Pharmaceuticals Ltd
Conditions
Prostate Cancer · Prostatic Neoplasms
Enrolling
383 people
Starts
2023-12-21
Est. completion
2026-09
Design
Open-label, single group, Phase 3
Record
View on ClinicalTrials.gov ↗